Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

31 July 2026

National Stock Exchange of India Limited
NSE Code: SUNPHARMA

BSE Limited
BSE Code: 524715

Outcome of the Board Meeting held today, i.e., 31 July 2026

Further to the communication dated 10 July 2026, this is to inform that the Board of Directors of the Company, at its meeting held today, has, inter alia,

1. **Approved Quarterly Financial Results**

   The Unaudited Standalone and Consolidated Financial Results for Q1 of FY 2026-27, as approved pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") along with the Limited Review Report, are annexed herewith as **Annexure A.**

2. **Press Release and Earnings Presentation**

   The press release outlining key updates for Q1 of FY 2026-27 is annexed herewith as **Annexure B**. It will be released soon after this communication. Also enclosed herewith is the Earnings Presentation as **Annexure C**.

The Board Meeting, which commenced at 10:50 AM, is ongoing and has been temporarily adjourned for a break and will resume for consideration of other agenda items. The outcome of the remaining matters, if any, shall be submitted upon conclusion of the meeting.

For **Sun Pharmaceutical Industries Limited**
Anoop Anjanikumar Deshpande
Digitally signed by Anoop Anjanikumar Deshpande
Date: 2026.07.31 14:17:46 +05'30'
(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India
Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Sun Pharmaceutical Industries Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Sun Pharmaceutical Industries Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

per Amit Singh
Partner
Membership No.: 408869
UDIN: 26408869LFSCDS3476
Place: Mumbai
Date: July 31, 2026

S R B C & CO LLP MUMBAI CHARTERED ACCOUNTANTS

Sun Pharmaceutical Industries Limited
Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012.
Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.
CIN: L24230GJ1993PLC019050, Website : www.sunpharma.com

Statement of Unaudited Standalone Financial Results for the Quarter ended June 30, 2026

(₹ in Million)

	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations				
	a. Revenue from contracts with customers	56,413.1	48,872.7	55,592.7	206,090.2
	b. Other operating revenues	998.2	366.1	356.1	1,456.2
	Total revenue from operations (I)	**57,411.3**	**49,238.8**	**55,948.8**	**207,546.4**
II	Other income	1,401.7	629.3	1,037.1	4,193.3
III	**Total income (I+II)**	**58,813.0**	**49,868.1**	**56,985.9**	**211,739.7**
IV	**Expenses**				
	Cost of materials consumed	12,397.4	12,286.6	9,979.3	43,832.7
	Purchases of stock-in-trade	2,750.4	3,119.1	3,282.5	13,915.2
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(192.2)	(3,453.7)	930.2	(3,058.3)
	Employee benefits expense	8,309.3	7,039.9	7,389.2	29,113.0
	Finance costs	2,784.8	2,169.2	2,384.2	9,478.4
	Depreciation and amortisation expense	3,079.2	3,259.7	3,109.2	13,117.2
	Other expenses	16,273.3	22,185.9	17,168.2	75,507.9
	Net (gain) / loss on foreign currency transactions	(1,769.0)	(5,228.7)	(1,895.9)	(13,571.0)
	Total expenses (IV)	**43,633.2**	**41,378.0**	**42,346.9**	**168,335.1**
V	**Profit / (loss) before exceptional items and tax (III-IV)**	**15,179.8**	**8,490.1**	**14,639.0**	**43,404.6**
VI	Exceptional items (Refer Note 3 and 4)	315.3	-	2,876.4	5,463.4
VII	**Profit / (loss) before tax (V-VI)**	**14,864.5**	**8,490.1**	**11,762.6**	**37,941.2**
VIII	(i) Tax expense / (credit)	3,792.4	2,150.2	5,317.1	13,363.2
	(ii) Tax expense / (credit) - Exceptional (Refer Note 3 and 4)	(79.3)	252.9	(1,005.1)	(1,656.2)
IX	**Profit / (loss) for the period (VII-VIII)**	**11,151.4**	**6,087.0**	**7,450.6**	**26,234.2**
X	**Other comprehensive income (OCI)**				
	a. (i) Items that will not be reclassified to profit or loss	42.2	(94.3)	(28.8)	(64.4)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(10.6)	26.1	10.5	16.2
	b. (i) Items that may be reclassified to profit or loss	1,886.5	(1,658.3)	330.6	(2,862.8)
	(ii) Income tax relating to items that may be reclassified to profit or loss	(474.8)	299.6	(115.5)	720.5
	Total other comprehensive income (a+b) (X)	**1,443.3**	**(1,426.9)**	**196.8**	**(2,190.5)**
XI	**Total comprehensive income for the period (IX+X)**	**12,594.7**	**4,660.1**	**7,647.4**	**24,043.7**
XII	Paid-up equity share capital - face value ₹ 1 each	**2,399.3**	**2,399.3**	**2,399.3**	**2,399.3**
XIII	Other equity				**221,308.3**
XIV	**Earnings per equity share of ₹ 1 each (not annualised for quarters)**				
	₹ (Basic)	**4.6**	**2.5**	**3.1**	**10.9**
	₹ (Diluted)	**4.6**	**2.5**	**3.1**	**10.9**
See accompanying notes to the unaudited standalone financial results					
Research and development expenses incurred (included above)		**4,635.9**	**6,797.0**	**6,146.9**	**21,635.0**

SIGNED FOR IDENTIFICATION
BY
ws
S R B C & CO LLP
MUMBAI

SUN PHARMACEUTICAL INDUSTRIES LIMITED
MUMBAI

Notes:

1 The above unaudited standalone financial results of Sun Pharmaceutical Industries Limited (the 'Company') have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 31, 2026.

2 The above unaudited standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ("Ind AS") as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3 Pursuant to the ongoing reassessment and refinement of employee compensation structures under the New Labour Codes framework, the Company recognised an incremental cost of ₹ 315.3 Million and a related tax credit of ₹ 79.3 Million for quarter ended June 30, 2026. (Also, refer note 4(b))

4 Exceptional items of ₹ 5,463.4 Million and Exceptional tax credit of ₹ 1,656.2 Million for year ended March 31, 2026 includes:

a) Discontinuation of development work of SCD-044, and includes, (i) Impairment of acquired intangible asset under development of ₹ 1,514.9 Million and (ii) Other costs of ₹ 1,361.5 Million (included in research and development expenses). Exceptional tax credit on this charge is ₹ 1,005.1 Million for the quarter ended June 30, 2025.

b) The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations.

The Company had assessed the implications of the New Labour Codes and had recognized an incremental cost of ₹ 2,587.0 Million and related tax credit of ₹ 904.0 Million during the quarter ended December 31, 2025. Further, as the Company opted for new regime under section 115BAA of the Income Tax Act, 1961 for FY 2026-27, the tax credit on the above impact was remeasured by ₹ 252.9 Million.

5 The Board of Directors of the Company at its meeting held on November 01, 2023 approved a Composite Scheme of Arrangement covering two aspects (1) Amalgamation of five wholly-owned subsidiaries (Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited and Skisen Labs Private Limited) (collectively "Transferor Companies") into the Company, and (2) Reclassification of general reserves to retained earnings with an appointed date of April 01, 2023.

On October 7, 2025, the National Company Law Tribunal approved the above scheme. As a result, the impact of the scheme for merger of Sun Pharmaceutical Medicare Limited including the tax credit on losses of ₹ 1,401.9 Million was taken during the year ended March 31, 2026 in accordance with Ind AS 103 – Business Combinations. The financial results for prior periods have been restated to reflect the effects of the merger.

The other subsidiaries did not constitute a business under IND AS 103, and were accounted as an asset acquisition. The impact on the financial position of the Company was not material on account of these subsidiaries.

6 With effect from the financial year 2026–27, the Company decided to exercise the option available under Section 115BAA of the Income-tax Act, 1961 (corresponding to Section 206 of the Income-tax Act, 2025), which provides eligible domestic companies a concessional tax regime at an effective rate of 25.168% (22% plus applicable surcharge and cess), in lieu of the regular corporate tax rate of 34.944%.

The Company had remeasured its deferred tax assets and liabilities at the new applicable rate as at March 31, 2026, in accordance with Ind AS 12, 'Income Taxes'. This resulted in a net credit to tax expense of ₹ 550.0 Million for the quarter and year ended March 31, 2026.

7 The figures for the quarter ended March 31, 2026 represent the derived figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited published year-to-date figures up to December 31, 2025, being the date of the end of third quarter of the financial year, which were subjected to a limited review by the statutory auditor of the Company.

8 The Company has only one reportable segment namely 'Pharmaceuticals'.

9 Figures for previous periods have been regrouped / reclassified wherever considered necessary.

SIGNED FOR IDENTIFICATION
BY
S R B C & CO LLP
MUMBAI

SUN PHARMACEUTICAL INDUSTRIES LIMITED
MUMBAI

For and on behalf of the Board

Kirti Ganorkar
Managing Director

Mumbai, July 31, 2026

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India
Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Sun Pharmaceutical Industries Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Sun Pharmaceutical Industries Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associates and joint venture for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors . Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the unaudited financial results of the entities mentioned in Annexure I to the Report.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S R B C & CO LLP
HS
MUMBAI
CHARTERED ACCOUNTANTS

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of 23 subsidiaries, whose financial results and other information without giving effect to the elimination of intra-group transactions reflect, Group's share of total revenue of INR 34,542.6 Million, total net profit after tax of INR 3,505.9 Million and total comprehensive income of INR 3,504.1 Million for the quarter ended June 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on interim financial results and other financial information of these entities have been furnished to us by management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries, is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

S R B C & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

per Amit Singh
Partner
Membership No.: 408869
UDIN: 26408869IDSNTN2745
Place: Mumbai
Date: July 31, 2026

Annexure I - List of entities included in the report of the unaudited Consolidated Financial Results

Sr. No.	Name of the entity
	Subsidiaries
1	Sun Pharmaceutical (Bangladesh) Limited
2	Sun Pharma De Mexico S.A. DE C.V.
3	Sun Pharma Japan Ltd.
4	Sun Pharma De Venezuela, C.A.
5	Sun Pharma Laboratories Limited
6	Neetnav Real Estate Private Limited
7	Sun Pharma Holdings
8	Softdeal Pharmaceutical Private Limited
9	Sun Pharma (Netherlands) B.V.
10	TARO Pharma Corporation Inc.
11	Zenotech Laboratories Limited
12	Sun Farmaceutica do Brasil Ltda.
13	Sun Pharma France
14	Sun Pharmaceutical Industries, Inc.
15	Ranbaxy (Malaysia) SDN. BHD.
16	Ranbaxy Nigeria Limited
17	Chattem Chemicals Inc.
18	The Taro Development Corporation
19	Alkaloida Chemical Company Zrt.
20	Sun Pharmaceutical Industries (Australia) Pty Limited
21	Aditya Acquisition Company Ltd.
22	Sun Pharmaceutical Industries (Europe) B.V.
23	Sun Pharmaceuticals Germany GmbH
24	Sun Pharma Philippines, Inc.
25	Caraco Pharmaceuticals Private Limited
26	Sun Pharmaceutical Peru S.A.C.
27	Sun Laboratories FZE
28	Taro Pharmaceutical Industries Ltd. (Taro)
29	Sun Pharma Canada Inc. (Formerly known as Taro Pharmaceuticals Inc.)
30	Taro Pharmaceuticals U.S.A., Inc.
31	Taro Pharmaceuticals North America, Inc.
32	Taro International Ltd.
33	3 Skyline LLC
34	One Commerce Drive LLC

S R B C & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

S R B C & CO LLP
Chartered Accountants

Sr. No.	Name of the entity
35	Sunpharma Middle East FZ LLC
36	2 Independence Way LLC
37	Universal Enterprises Private Limited
38	Sun Pharma Switzerland Ltd.
39	Sun Pharma East Africa Limited
40	PI Real Estate Ventures, LLC
41	Sun Pharma ANZ Pty Ltd.
42	Ranbaxy Farmaceutica Ltda.
43	Sun Pharma Egypt LLC
44	Rexcel Egypt LLC
45	Basics GmbH
46	Sun Pharma Italia srl
47	Sun Pharmaceutical Industries S.A.C.
48	Ranbaxy (Poland) SP. Z O.O.
49	Terapia SA
50	AO Ranbaxy
51	Ranbaxy South Africa (Pty) Ltd.
52	Ranbaxy Pharmaceuticals (Pty) Ltd.
53	Sonke Pharmaceuticals Proprietary Limited
54	Sun Pharma Laboratorios, S.L.U.
55	Sun Pharma UK Limited
56	Sun Pharma Holdings UK Limited
57	Ranbaxy Inc.
58	Ranbaxy (Thailand) Co., Ltd.
59	Ohm Laboratories, Inc.
60	Ranbaxy Signature LLC
61	Sun Pharmaceuticals Morocco LLC
62	"Ranbaxy Pharmaceuticals Ukraine" LLC
63	JSC Biosintez
64	Sun Pharmaceuticals Holdings USA, Inc.
65	Zenotech Inc.
66	Zenotech Farmaceutica Do Brasil Ltda.
67	Sun Pharma Distributors Limited
68	Realstone Infra Limited
69	Sun Pharmaceuticals (EZ) Limited
70	Sun Pharma (Shanghai) Co. Ltd.
71	Alchemee, LLC

S R B C & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

Sr. No.	Name of the entity
72	The Proactiv Company Holdings, Inc.
73	Proactiv YK
74	The Proactiv Company KK
75	Alchemee Skincare Corporation
76	Concert Pharma Ireland Limited [Dissolved as of June 1, 2026]
77	Sun Pharma New Milford Parent LLC
78	Sun Pharma Housatonic LLC
79	Sun Pharma Housatonic II LLC
80	Sun Pharma Housatonic III LLC
81	Vivaldis Health and Foods Private Limited
82	Sun Pharma Community Health Care Society
83	Sun Pharma Science Foundation
84	Sun Pharmaceuticals North Africa SA (formerly known as Kemipharm)
85	Sun Pharma Luxembourg S.A (formerly known as Valstar S.A.)
86	Checkpoint Therapeutics, Inc.
87	Sun Pharma (Hainan) Company Limited [Date of Incorporation July 16, 2025]
88	Foundation for Disease Elimination and Control of India
89	Sun Pharma America, INC. [Incorporated on April 23, 2026]
	Joint Venture
1	Artes Biotechnology GmbH
	Associates
1	Medinstill LLC
2	Trumpcard Advisors and Finvest LLP
3	Tarsier Pharma Ltd.
4	WRS Bioproducts Pty Ltd.
5	Remidio Innovative Solutions Private Limited
6	Agatsa Software Private Limited
7	Ezerx Health Tech Private Limited
8	Surgimatix, Inc
9	Indian Foundation for Quality Management
10	Haystackanalytics Private Limited
11	Pharmazz Inc.

Note: Number of subsidiaries reported under para 6 of the auditor's review report have been reported on a consolidated basis for certain subsidiaries having step-down subsidiaries, joint venture and associates.

S R B C & CO LLP * MUMBAI * CHARTERED ACCOUNTANTS
HS

Sun Pharmaceutical Industries Limited

Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012.

Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.

CIN: L24230GJ1993PLC019050, Website : www.sunpharma.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026

(₹ in Million)

	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations				
a.	Revenue from contracts with customers	151,835.5	145,597.5	137,860.7	582,201.1
b.	Other operating revenues	1,163.3	520.4	653.3	2,419.3
	Total revenue from operations (I)	**152,998.8**	**146,117.9**	**138,514.0**	**584,620.4**
II	Other income	7,236.2	4,585.0	4,644.6	19,717.2
III	**Total income (I+II)**	**160,235.0**	**150,702.9**	**143,158.6**	**604,337.6**
IV	**Expenses**				
	Cost of materials consumed	20,262.8	21,824.4	17,715.9	73,890.2
	Purchases of stock-in-trade	10,195.0	7,533.4	10,479.8	38,115.3
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(826.2)	(1,346.9)	(48.1)	3,431.3
	Employee benefits expense	32,272.3	29,604.1	28,016.6	114,188.6
	Finance costs	996.7	858.9	748.0	3,389.1
	Depreciation and amortisation expense	7,387.2	7,754.7	7,005.5	29,378.5
	Other expenses	48,138.1	53,228.4	41,623.6	190,082.8
	Net (gain) / loss on foreign currency transactions	(1,219.9)	(4,267.5)	(2,290.4)	(12,401.8)
	Total expenses (IV)	**117,206.0**	**115,189.5**	**103,250.9**	**440,074.0**
V	**Profit / (loss) before exceptional items and tax (III-IV)**	**43,029.0**	**35,513.4**	**39,907.7**	**164,263.6**
VI	Exceptional items (Refer Note 4 and 5)	2,040.9	-	8,180.0	13,074.8
VII	**Profit / (loss) before tax (V-VI)**	**40,988.1**	**35,513.4**	**31,727.7**	**151,188.8**
VIII	(i) Tax expense/(credit)	11,974.4	7,909.4	9,706.6	39,397.6
	(ii) Tax expense/(credit) - Exceptional (Refer Note 4 and 5)	(94.3)	366.8	(1,005.1)	(3,854.0)
IX	**Profit / (loss) before share of profit / (loss) of associates and joint venture (VII-VIII)**	**29,108.0**	**27,237.2**	**23,026.2**	**115,645.2**
X	Share of profit / (loss) of associates and joint venture (net)	(95.7)	(140.6)	(97.5)	(558.7)
XI	**Net Profit / (loss) after taxes and share of profit / (loss) of associates and joint venture but before non-controlling interests (IX+X)**	**29,012.3**	**27,096.6**	**22,928.7**	**115,086.5**
	Non-controlling interests	64.4	(43.7)	142.4	292.3
XII	**Net Profit / (loss) after taxes, share of profit / (loss) of associates and joint venture and non-controlling interests**	**28,947.9**	**27,140.3**	**22,786.3**	**114,794.2**
XIII	**Other comprehensive income (OCI)**				
a.	(i) Items that will not be reclassified to profit or loss	12,403.7	(737.0)	(2,844.1)	3,029.4
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(888.7)	(137.5)	739.4	(1,128.0)
b.	(i) Items that may be reclassified to profit or loss	3,919.0	15,593.9	3,507.0	35,644.0
	(ii) Income tax relating to items that may be reclassified to profit or loss	(342.5)	314.3	(128.1)	722.0
	Total other comprehensive income (a+b) (XIII)	**15,091.5**	**15,033.7**	**1,274.2**	**38,267.4**
XIV	**Total comprehensive income (XI+XIII)**	**44,103.8**	**42,130.3**	**24,202.9**	**153,353.9**
	Attributable to:				
	- Owners of the Company	44,083.2	42,135.3	23,959.2	152,811.1
	- Non-controlling interests	20.6	(5.0)	243.7	542.8
XV	Paid-up equity share capital - face value ₹ 1 each	2,399.3	2,399.3	2,399.3	2,399.3
XVI	Other equity				833,301.6
XVII	**Earnings per equity share of ₹ 1 each (not annualised for quarters)**				
	₹ (Basic)	12.1	11.3	9.5	47.8
	₹ (Diluted)	12.1	11.3	9.5	47.8
	See accompanying notes to the unaudited consolidated financial results				
	Research and development expenses incurred (included above)	8,076.6	9,500.3	8,841.0	34,741.0

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

SUN PHARMACEUTICAL INDUSTRIES LIMITED
MUMBAI

Notes :

1 These unaudited consolidated financial results relate to Sun Pharmaceutical Industries Limited (the 'Company'), its Subsidiaries (together the 'Group'),Joint Venture and Associates and are prepared by applying Ind AS 110 - "Consolidated Financial Statements", and Ind AS 28 - "Investments in Associates and Joint Ventures".

2 The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 31, 2026.

3 The above unaudited consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ("Ind AS") as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

4 Exceptional items of ₹ 2,040.9 Million and Exceptional tax credit of ₹ 94.3 Million for quarter ended June 30, 2026 includes :

a) Charge of ₹ 1,670.0 Million towards due diligence, legal, filing fees, and other acquisition-related and transaction costs incurred in relation to the definitive agreement to acquire all outstanding shares of Organon & Co. Additional acquisition-related costs are expected to be incurred in subsequent periods.

b) Pursuant to the ongoing reassessment and refinement of employee compensation structures under the New Labour Codes framework, the Company recognized an incremental cost of ₹ 370.9 Million and a related tax credit of ₹ 94.3 Million. [Also, refer note 5(c)]

5 Exceptional items of ₹ 13,074.8 Million and Exceptional tax credit of ₹ 3,854.0 Million for year ended March 31, 2026 includes :

a) Charge of ₹ 2,876.4 Million on account of discontinuation of development work of SCD-044, which includes (i) Impairment of acquired intangible asset under development of ₹ 1,514.9 Million and (ii) Other costs of ₹ 1,361.5 Million (included in research and development expenses). Tax credit on this charge was ₹ 1,005.1 Million in quarter ended June 30, 2025.

b) On July 24, 2025 Taro and Sun Pharmaceutical Industries, Inc. (SPIINC) entered into a settlement agreement with the putative End Payer Plaintiffs class ("EPPs") without any admission of guilt or violation of any statute, law, rule or regulation, or of any liability or wrongdoing, pursuant to which Taro and SPIINC agreed to pay an aggregate amount of USD 200.0 Million (equivalent to ₹ 17,112.0 Million), in exchange for a full release of all claims asserted against them (and all of their current and former parents, affiliates, predecessors and successors as well as their current and former directors, officers, employees and representatives). The Company had taken a charge of USD 62.0 Million (equivalent to ₹ 5,303.6 Million) inclusive of legal charges of USD 7.0 Million (equivalent to ₹ 598.9 Million) (net of amount already provided in previous years) as an exceptional item during the quarter ended June 30, 2025. The settlement agreement was subject to court approval, and the court issued its order of approval on January 23, 2026, dismissing the EPP matters on the merits, in their entirety, with prejudice. Further to the courts approval and final opt-outs percentage, an additional charge of USD 12.8 Mn (equivalent to ₹ 1,139.5 Million) inclusive of legal charge of USD 7.8 Mn (equivalent to ₹ 693.8 Million) was taken. Tax credit on this settlement charge was ₹ 1,904.5 Million for the quarter ended December 31, 2025.

c) The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes became effective from November 21, 2025 and introduced changes that include, among other things, setting a uniform definition of wages. The Government is in process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations.

The Company had assessed the implications of the New Labour Codes and had recognized an incremental cost of ₹ 3,755.3 Million and related tax credit of ₹ 1,311.2 Million during the quarter ended December 31, 2025. Further, as the Company opted for new regime under section 115BAA of the Income Tax Act, 1961 for FY 2026-27, the tax charge on the above impact was remeasured by ₹ 366.8 Million.

6 The Board of Directors of the Company at its meeting held on November 01, 2023 approved a Composite Scheme of Arrangement covering two aspects (1) Amalgamation of five wholly-owned subsidiaries (Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited and Skisen Labs Private Limited) (collectively "Transferor Companies") into the Company, and (2) Reclassification of general reserves to retained earnings with an appointed date of April 01, 2023.

On October 7, 2025, the National Company Law Tribunal approved the above scheme. As a result, the impact of the scheme for merger of Sun Pharmaceutical Medicare Limited including the tax credit of ₹ 1,401.9 Million on losses was taken during year ended March 31, 2026 in accordance with Ind AS 103 – Business Combinations.

7 With effect from the financial year 2026–27, the Company and one of its Indian subsidiary decided to exercise the option available under Section 115BAA of the Income-tax Act, 1961 (corresponding to Section 206 of the Income-tax Act, 2025), which provides eligible domestic companies a concessional tax regime at an effective rate of 25.168% (22% plus applicable surcharge and cess), in lieu of the regular corporate tax rate of 34.944%.

The Company had remeasured its deferred tax assets and liabilities at the new applicable rate as at March 31, 2026, in accordance with Ind AS 12, 'Income Taxes'. This resulted in a net credit to tax expense of ₹1,030.0 Million in the quarter and year ended March 31, 2026.

8 On April 27, 2026, the Group entered into a definitive agreement to acquire all outstanding shares of Organon & Co. for cash payment of USD 14.00 per share in an all cash transaction with an enterprise valuation of USD 11.75 billion. Acquisition is subject to approvals and closing conditions.

9 The Group has only one reportable segment namely 'Pharmaceuticals'.

10 The figures for the quarter ended March 31, 2026 represent the derived figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited published year-to-date figures up to December 31, 2025, being the date of the end of third quarter of the financial year, which were subjected to a limited review by the statutory auditor of the Company.

11 Figures for previous periods have been regrouped / reclassified wherever considered necessary.

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

SUN PHARMACEUTICAL INDUSTRIES LIMITED
MUMBAI

For and on behalf of the Board

Kirti Ganorkar
Managing Director

Mumbai, July 31, 2026

Annexure -B

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

FOR IMMEDIATE RELEASE

Sun Pharma reports Q1FY27 results

Q1 Sales at Rs. 151,836 million up 10.1% YoY
Q1 Net profit increased to Rs. 28,948 million

Mumbai, July 31, 2026: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) reported financials for the first quarter ending June 30th, 2026.

Highlights of Q1FY27 consolidated financials*

- Sales at Rs. 151,836 million, a growth of 10.1%
- Global Innovative Medicines sales at US$ 351 million, up 12.8% and accounting for 21.9% of sales.
- EBITDA at Rs. 44,177 million, up 2.7%. EBITDA margin at 28.9%.
- Adjusted net profit was Rs. 30,894 million, up 3.1%
- R&D investment was Rs. 8,264 million at 5.4% of sales

**Growth measured vs same period last financial year*

Kirti Ganorkar, Managing Director of the Company, said, "Our performance during the quarter was driven by strong momentum in India as well as Innovative Medicines, which delivered robust growth across the U.S. and international regions. Recent semaglutide approvals in India, Brazil and South Africa underscore our capabilities in developing complex peptide products for patients globally. Organon shareholders have approved the proposed acquisition by Sun, which is on track to close in early 2027."

India Formulations

Formulation sales in India were Rs. 54,749 million, registering a growth of 16%. India Formulation sales accounted for 36.1% of total consolidated sales.

Sun Pharma continues to be India's No. 1 Pharma Company. Sun's market share increased to 8.5% from 8.2%, as per the Pharmarack MAT June-2026 report. As per SMSRC (Mar-Jun 2026) report, Sun Pharma enjoys No.1 ranking by prescriptions in 12 different doctor categories. For Q1FY27, the company launched 5 new products in the Indian market.

US Formulations

Formulation sales in the US were US$ 427 million, lower by 9.7%. Innovative Medicines continued to grow, partially offsetting the decline in generics business. US sales accounted for approximately 26.6% of total consolidated sales.

Emerging Markets (EM) Formulations

Emerging Markets formulations sales were US$ 311 million, up by 4.2% and accounted for 19.4% of total consolidated sales.

Rest of World (ROW) Formulations

Formulation sales in Rest of World markets were US$ 218 million and accounted for 13.6% of total consolidated sales.

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

Innovative Medicines

Global Innovative Medicines sales were US$ 351 million for Q1FY27, up 12.8% and accounted for 21.9% of sales.

Active Pharmaceutical Ingredients (API)

Our API portfolio supports our formulation business and API customers across geographies. External sales of API were Rs. 5,972 million, up 10.5%.

R&D Update

Sun Pharma's R&D efforts span across both innovative and generic businesses and the company continues to invest in building the pipeline for various markets. Sun's innovative R&D pipeline includes five novel entities in clinical stage. Sun has a comprehensive product offering in the US market consisting of approved ANDAs for 558 products while filings for 119 ANDAs await US FDA approval, including 28 tentative approvals. During the quarter, 3 ANDAs were filed, and approval received for 6 ANDAs.

Sun's portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval.

Innovative Medicines Pipeline

Candidate	Indication	Current phase	Next milestone
Ilumya	psoriatic arthritis	Supplement filed with US FDA	PDUFA Date: Oct-26
Fibromun	soft tissue sarcoma	Phase 2 completed	Start of Phase 3
	glioblastoma	Phase 2	Regulatory filing
GL0034	type 2 diabetes	Phase 2	Topline data during 2HCY27
Nidlegy™ (EU, ANZ rights with Sun)	locally advanced melanoma	Filing with EMA	Approval and launch
	locally advanced BCC	Phase 2	Regulatory filing
	locally advanced cSCC	Phase 2	Regulatory filing
Candidate for partnering			
MM-II	pain in osteoarthritis	Phase 2 completed	To enter partnership for commercialization

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

SUN PHARMA

Sales and R&D snapshot

(₹ in mn)

Particulars	**Quarter ended**			**Year ended**
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
India Formulations	54,748.9	48,358.9	47,211.0	192,903.6
US Formulations	40,419.1	41,997.1	40,452.1	168,242.2
EM Formulations	29,456.3	27,970.5	25,531.4	111,864.8
ROW Formulations	20,685.8	20,139.7	18,735.9	85,684.0
Total Formulations	**145,310.1**	**138,466.2**	**131,930.4**	**558,694.6**
API	5,972.3	6,738.6	5,403.7	21,852.6
Others	553.1	392.7	526.6	1,653.9
Total Sales	**151,835.5**	**145,597.5**	**137,860.7**	**582,201.1**
Total R&D Expenditure	**8,263.5**	**9,757.3**	**9,028.6**	**35,540.1**
Capital	186.9	257.0	187.6	799.1
Revenue	8,076.6	9,500.3	8,841.0	34,741.0
Exchange Rates : US$ 1 = ₹	94.70	91.49	85.56	

Earnings Call (06.30 pm IST, July 31, 2026)

The Company will host earnings call at 06.30 pm IST on July 31, 2026, where senior management will discuss the Company's performance and answer questions from participants. This call will be accessible through an audio dial-in and a webcast.

Audio conference	Participants can dial-in on the numbers below Universal number: +91 22 6629 0049 +91 22 7194 5729
Pre-registration details	Click here DiamondPassRegistration
Webcast	*More details will be provided through our website, www.sunpharma.com*

To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available at www.sunpharma.com. The playback will be available for a few days.

Disclaimer

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 22% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).

Contacts

Investors
Dr. Abhishek Sharma

Tel	+91 22 4324 4324, Xtn 2929
Tel Direct	+91 22 4324 2929
Mobile	+91 98196 86016
E mail	abhi.sharma@sunpharma.com

Media
Gaurav Chugh

Tel	+91 22 4324 4324, Xtn 5373
Tel Direct	+91 22 4324 5373
Mobile	+91 98104 71414
E mail	gaurav.chugh@sunpharma.com

Annexure -C

SUN PHARMA

Q1 FY27

Earnings Presentation

31st July 2026

NSE:SUNPHARMA | BSE:524715 |
Bloomberg:SUNP IN |
Reuters:SUN.BO

WWW.SUNPHARMA.COM

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Sun Pharmaceutical Industries Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Performance Highlights

Q1FY27 Performance	Innovative Medicine focus	Financial Prudence
Sales Growth at 10.1% EBITDA Margin for the quarter at 28.9% With our presence in 100+ countries, Sun Pharma continues to solidify global reach	**Global Innovative Medicines continues to deliver strong growth at 12.8%** for the quarter Innovative Medicines remain key to our strategy	Strong balance sheet, with **Net Cash position of US$ 3.4 bn**

Financial Snapshot

(₹ mn)	Q1FY27	Q1FY26	Y-o-Y
Sales	**1,51,836**	1,37,861	10.1%
Gross Margin %	**80.5%**	79.6%	
EBITDA	**44,177**	43,017	2.7%
EBITDA%	**28.9%**	31.1%	
Reported PAT	**28,948**	22,786	
Adjusted PAT	**30,894**	29,961	3.1%
EPS	**12.1**	9.5	

Q1FY27 : Sales of ₹ 151.8 bn, 10.1% growth over last year, with Profit After Tax of ₹ 28.9 bn

Revenue Snapshot



Note: Numbers shown are Sales excluding Other Operating Revenue

Innovative Medicines

Sales (US$ mn)



ILUMYA® tildrakizumab-asmn Injection 100 mg/mL

Cequa™ (cyclosporine ophthalmic solution) 0.09%

Odomzo® (sonidegib) capsules 200mg

Winlevi® (clascoterone) cream 1%

LEVULAN® KERASTICK® (aminolevulinic acid HCl) for Topical Solution, 20% + BLU-U® Blue Light Photodynamic Therapy Illuminator Model 4170

LEQSELVI™ (deuruxolitinib) tablets 8mg

UNLOXCYT™ (cosibelimab-ipdl) Injection 300mg

- ✓ Growth of 12.8% in Q1FY27, driven by both US & international markets
- ✓ Global Innovative Medicines sales forms 21.8% of total consolidated sales for the quarter

India Formulations

Sales (₹ mn)



Sustained Market Share* Growth



- ✓ In Q1, India formulations recorded growth of 16%, led by CVD, CNS, Gastro-Ortho segments
- ✓ Sustained market share growth; 0.3pp gain over the year to reach 8.5%
- ✓ India Formulations forms 36.1% of total consolidated sales for the quarter

* Market Share as per Pharmarack MAT-Jun'26

US Formulations

Sales (US$ mn)







- ✓ US Formulations declined by 9.7% in Q1FY27, to US$ 427 mn.
- ✓ Ilumya, Cequa & Odomzo led growth for IM, offset by a decline in Generics, including lenalidomide
- ✓ For Q1FY27, US Formulations forms 26.6% of total consolidated sales for the quarter

Emerging Markets Formulations

Sales (US$ mn)



Focus Markets

- Romania
- Brazil
- South Africa
- Mexico

- ✓ Emerging Markets recorded Q1FY27 Revenue of US$ 311 mn, 4.2% higher than last year
- ✓ Emerging Markets Formulations form 19.4% of total consolidated sales for the quarter
- ✓ Innovative Medicines portfolio continues to drive growth in Emerging Markets

Rest of World Formulations

Sales (US$ mn)



Focus Markets

- Western Europe
- Canada
- Japan
- Australia & NZ

- ✓ RoW Formulations recorded Q1FY27 Revenue of US$ 218 mn
- ✓ RoW Formulations form 13.6% of total consolidated sales for the quarter

R&D Update

Candidate	Indication	Current phase	Next milestone
Ilumya	psoriatic arthritis	Supplement filed with US FDA	PDUFA Date: Oct-26
Fibromun	soft tissue sarcoma	Phase 2 completed	Start of Phase 3
	glioblastoma	Phase 2	Regulatory filing
GL0034	type 2 diabetes	Phase 2	Topline data during 2HCY27
Nidlegy™ (EU, ANZ rights with Sun)	locally advanced melanoma	Filing with EMA	Approval and launch
	locally advanced BCC	Phase 2	Regulatory filing
	locally advanced cSCC	Phase 2	Regulatory filing
Candidate for partnering			
MM-II	pain in osteoarthritis	Phase 2 completed	To enter partnership for commercialization

- ✓ In Q1FY27, R&D investments were at 5.4% of sales
  - ✓ Of the total R&D spend, 30% was for Innovative Medicines R&D

Organon Acquisition Update

1. Signed definitive docs with Organon on 27th April 2026

2. Ongoing deal closure
   - US HSR & a few other countries' approvals received
   - Organon received Shareholders' approval on 23rd July

3. Sun and Organon will continue to work as independent entities till deal closure.

4. Integration Planning post-closing
   - Integration Management Office working on Day 1 preparedness.

5. Indicative closure of proposed transaction by Q4FY27

For more information, please contact

Investors

Dr. Abhishek Sharma
Tel : +91 22 4324 4324, Xtn 2929
Tel Direct +91 22 4324 2929
abhi.sharma@sunpharma.com

Corporate Address

SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063

NSE:SUNPHARMA, BSE: 524715, Reuters: SUN.BO, Bloomberg: SUNP IN
CIN: L24230GJ1993PLC019050
www.sunpharma.com